VolitionRx is focusing next on a massive European clinical trial of its new colorectal cancer blood test in the wake of promising preliminary results from a smaller study in Germany. Success in the coming months will help support the company's plans to pursue a CE mark in 2014 and FDA approval the year after.
Quest Diagnostics' ongoing revamp continued this week with news that an Australian company has snatched up its colorectal cancer screening test business. Neither side is commenting on the financial details.
Israel's Given Imaging notched a best-ever second quarter, nearly doubling its net profit and increasing revenue by 11% as it wins more and more approvals for the PillCam.
Given Imaging now has Japan's regulatory sign-off for its new endoscopic pill camera, creating a new avenue for revenue growth in the world's second largest healthcare market.
Colon cancer often isn't detected until it is advanced and often harder to treat. Baylor Research Institute scientists believe they've come up with a blood test that could catch it drastically earlier--even before it formally takes hold in the body.
In 15 years, Germany's Epigenomics has experienced a heady series of ups and downs. The Berlin-based diagnostics company went public on the Frankfurt stock exchange in 2004 and raised €41.6 million. It merged with a Seattle operation that is now its U.S. arm and gained CE marks for a colon cancer early-detection diagnostic and a lung cancer confirmatory assay. But over the last two years, there was also the restructuring. Read more >>
Early detection boosts colon cancer survival rates. The Yonsei University College of Medicine in Seoul, South Korea, and Genomictree believe they can accomplish this goal, thanks to a noninvasive biomarker blood test that appears to be highly accurate based on initial clinical work.
Using lipids derived from grapefruits, researchers at the University of Louisville have created nanoparticles for drug delivery that are less toxic to both people and the environment and may offer a less expensive alternative to synthetic materials.
A new therapeutic may be more effective against a variety of cancers--including colon, head and neck, mesothelioma, ovarian and pancreatic cancers--than previously thought.
Mode Diagnostics wants European regulatory approval in 2013 for a do-it-your-self home test for colon cancer, with an eye toward an FDA-signoff within18 months thereafter. And that's big news for the industry at large.